What weight-loss medication costs

This is the question that dominates everything else, and the answer turns on a category decision your plan made before you ever asked. Weight management is among the most commonly excluded categories in US drug coverage.

• Does the plan cover weight management at all, as a category? Many exclude it outright regardless of brand.
• Has your employer added a carve-out that differs from the insurer's standard formulary?
• Is the specific brand on the formulary, and at what tier?
• Is prior authorisation required, and what criteria must be documented?
• Is step therapy required — must you try something else first?
• Is there a separate diabetes indication in your record that changes the picture?

Ask your plan these directly rather than asking a clinic. A clinic can tell you what usually happens; only your plan can tell you what happens for you.

Knowing that plans exclude weight management is not the same as knowing how to get a decision changed. The mechanics are worth understanding because most of the levers sit with your prescriber rather than with you.

Prior authorisation is the usual gate. Your prescriber submits documentation against criteria the plan has written in advance — typically some combination of diagnosis, prior attempts, and comorbid conditions. The criteria are specific and the submission either meets them or does not; this is a documentation exercise more than a persuasion exercise, which is why a practice that does this often is materially better at it than one that does not.

Formulary tier determines what you pay when it is covered. A medicine on a specialty tier can carry a very different cost share from the same medicine on a preferred tier, and tier placement changes between plan years.

The indication on the prescription frequently decides the whole thing. Plans commonly exclude weight-management indications while covering the identical molecule prescribed for type 2 diabetes or for cardiovascular risk reduction. This is not a loophole to exploit — the prescription must reflect your actual clinical situation — but it explains why two people can be prescribed the same drug and get opposite answers.

Employer carve-outs sit on top of all of it. A self-funded employer can add or remove this category independently of the insurer's standard formulary, which is why colleagues on the same insurer can have different coverage.

If the answer is no, there is an appeals process, and it has deadlines. Ask the plan for the denial reason in writing and for the appeal timeline at the same time, because the second is easy to miss while dealing with the first.

Under current policy, anti-obesity medications are coverable under Medicare Part D only where the drug is being used for another medically accepted indication — type 2 diabetes, or reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight — rather than for weight loss or weight management itself.

CMS has proposed reinterpreting the statute so that anti-obesity medications would no longer be excluded from Part D coverage for treating obesity, and separately has launched a time-limited access route for Part D enrollees at a fixed monthly amount it sets. Both of those are live and changing.

We are deliberately not printing figures or predicting where this lands. Confirm the current position with CMS or your plan rather than relying on any page, including this one.

Manufacturer savings programmes are the most commonly misunderstood row. They are generally conditional on having commercial insurance, which means the people with the least coverage often cannot use them.

Compounded programmes typically quote a flat monthly subscription. We do not publish those figures because they vary by programme and have moved substantially as the regulatory position changed.

What is worth understanding is what the price reflects. A compounded preparation is not a generic — there is no approved generic of either molecule — so a lower price is not the result of patent expiry and normal generic competition. It reflects a different preparation route with a different regulatory basis, and since the shortages were declared resolved, a narrower one.

• Is the advertised rate introductory, and what is the ongoing rate?
• What is the commitment period, and what happens if you stop?
• Are consultations and any laboratory work inside the subscription?
• Which pharmacy prepares it and under what authority?

The regulatory basis is the part most price comparisons omit. US law splits compounders into two categories: a 503A pharmacy compounds for an individual patient against a prescription and is exempt from federal requirements for approval, current good manufacturing practice and certain labelling. A 503B outsourcing facility registers with FDA, is subject to CGMP, is inspected on a risk-based schedule, and may distribute without a patient-specific prescription. Those are different cost structures as well as different oversight regimes, and a quote rarely tells you which one you are buying from.

Sitting over both is FDA's "essentially a copy" test, which regards a compounded product with the same active ingredient as a commercially available drug, at the same or an easily substitutable strength and by the same route, as a copy unless a prescriber documents a significant difference for a specific patient. How that applies to any given preparation now the shortages are resolved is exactly what remains unsettled, and we hold it in the under-review register rather than stating it as settled.

One concrete warning that belongs in a cost discussion: FDA has documented fraudulent compounded semaglutide and tirzepatide with false label information, including products naming compounding pharmacies that do not exist and products naming real licensed pharmacies that did not make them. An unusually low number is a reason to verify the pharmacy on the label, not a bargain to move on quickly.

Tirzepatide pricing behaves slightly differently from semaglutide pricing, and it is worth separating the levers.

• Dose tier. Pricing frequently steps with strength, so the figure quoted at the start is often not the figure you settle at.
• Branded versus compounded supply, which is a difference in regulatory category rather than a discount on the same product.
• Channel — retail counter, manufacturer direct-to-consumer self-pay, telehealth bundle, or a cash compounding programme. These are not comparable prices because they do not contain the same things.
• Programme bundling: whether consultations, laboratory work, dose changes and shipping sit inside the monthly figure or outside it.
• Introductory rates expiring, which is the most common unpleasant surprise and usually lands in month three or four.

The useful request to make of any programme is the total twelve-month cost at the dose you expect to be on, itemised. A service unwilling to put that in writing has answered a different question than the one you asked.

Ask for the twelve-month total in writing, assuming you continue and assuming any introductory rate ends. Compare programmes on that figure rather than on the first month.

Dosing is determined by a licensed provider, and what you are prescribed affects what you pay.

How we verify providers

• CMS — Contract Year 2026 Policy and Technical Changes to the Medicare Advantage and Part D Programs (CMS-4208-P) fact sheet — retrieved 2026-08-06
• CMS — CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications — retrieved 2026-08-06
• FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — retrieved 2026-08-06
• FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — retrieved 2026-08-06
• FDA — Human Drug Compounding Laws — retrieved 2026-08-06
• FDA — Information for Outsourcing Facilities — retrieved 2026-08-06